Skip to content

Research on the repeatability of measuring tissue properties with MRI

Test-retest validation of quantitative MRI - test-retest MRI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50975
Enrollment
208
Registered
2021-06-21
Start date
2022-04-24
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate carcinoma, liver metastases, lung carcinoma and metastases, rectum carcinoma, abdominal carcinoma prostate cancer, liver metastases, lung cancer and metastases, rectum cancer, cancer in abdomen cavity

Interventions

Magnetic Resonance Imaging (MRI)

Sponsors

Antoni van Leeuwenhoek (AVL)
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age >= 18 years, who receive an MRI for preparation of their treatment with radiotherapy and/or who receive radiation treatment on the MRL - WHO performance status 0-2 - ability to understand and willingness to sign a written informed consent

Exclusion criteria

Exclusion criteria: - Contra-indications for an MRI examination - Pregnancy - Claustrophobia - Over 140 kg and/or a body with over 60 cm - Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable fot the patient to participate in the stydy or which jeopardize compliance with study requirements or severe psychiatric illness/social situation

Design outcomes

Primary

MeasureTime frame
The main study parameter is the repeatability coefficient (within-coefficient of variance) between the quantitative MRI values measured during the test and retest.

Countries

Netherlands

Contacts

Public ContactM.E. Nowee

Antoni van Leeuwenhoek (AVL)

RTstudieondersteuning@nki.nl0205129111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026